Denosumab Advisory Committee Must Juggle Robust Efficacy With FDA's Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Concerns about infections and facture healing with Amgen's Prolia could lead to a recommendation for a REMS.